Pancreatic Cancer Research

Clinical trialPhase 2Withdrawn

The Effect of Cannabis in Pancreatic Cancer

The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer

NCT03245658↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Stopped earlyOrganization was changed. The staff was relocated. (Other)
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Start
6 October 2017
Expected end
6 October 2018
Enrollment
0 participants
Sites
1
Primary outcomes
Energy and protein intake
Sponsor
Other
Results posted
No
Last update
18 December 2023

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.

Detailed description public domain (ClinicalTrials.gov)

Randomization of consecutive patients who wanted to participate to a daily dose of CBD or not as a supplement to the standard treatment.

Papers 12